Adverum Faces Rocky Road As It Switches Gears From DME To Wet AMD

Gene Therapy Company Calls Off Diabetic Macular Edema Program

 
• By Alaric DeArment
  
Eye
Adverum is shifting the focus of its gene therapy from DME to wet AMD, but it faces a challenging path forward • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D